Article Text

Download PDFPDF
Review: evidence for major benefits and harms of antidiabetic agents for diabetes with heart failure is limited

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

A Johnson

Dr A Johnson, University of Alberta, Edmonton, Alberta, Canada;



in patients with heart failure (HF) and diabetes, what is the relation between antidiabetic therapy and morbidity and mortality?

Search methods:

Medline (1966–2007), EMBASE/Excerpta Medica (1980–2007), Cochrane Central Register of Controlled Trials (1991–2007), 5 other databases, reference lists, and experts.

Study selection and assessment:

randomised controlled trials (RCTs) or cohort studies evaluating the association between antidiabetic drugs (insulin, metformin [MET], sulphonylurea [SU], and thiazolidinedione [TZD]) and hospital admission or all-cause mortality in patients with HF and diabetes. Quality assessment of individual studies was based on a validated checklist (maximum score 32; scores ⩾12 indicate acceptable quality). 8 studies met the selection criteria: 1 RCT, 2 posthoc …

View Full Text


  • Source of funding: Alliance for Canadian Health Outcomes Research in Diabetes.